Literature DB >> 27398832

Human Vaccines & Immunotherapeutics: News.

.   

Abstract

Entities:  

Year:  2016        PMID： 27398832      PMCID： PMC4964828          DOI： 10.1080/21645515.2016.1201369

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  6 in total

1.  Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.

Authors:  Erlend Strønen; Mireille Toebes; Sander Kelderman; Marit M van Buuren; Weiwen Yang; Nienke van Rooij; Marco Donia; Maxi-Lu Böschen; Fridtjof Lund-Johansen; Johanna Olweus; Ton N Schumacher
Journal:  Science       Date:  2016-05-19       Impact factor: 47.728

2.  Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer.

Authors:  Weimin Wang; Ilona Kryczek; Lubomír Dostál; Heng Lin; Lijun Tan; Lili Zhao; Fujia Lu; Shuang Wei; Tomasz Maj; Dongjun Peng; Gong He; Linda Vatan; Wojciech Szeliga; Rork Kuick; Jan Kotarski; Rafał Tarkowski; Yali Dou; Ramandeep Rattan; Adnan Munkarah; J Rebecca Liu; Weiping Zou
Journal:  Cell       Date:  2016-04-28       Impact factor: 41.582

3.  Long-Term Progression-Free and Overall Survival in Two Melanoma Patients Treated with Patient-Specific Therapeutic Vaccine Eltrapuldencel-T After Resection of a Solitary Liver Metastasis.

Authors:  Robert O Dillman
Journal:  Cancer Biother Radiopharm       Date:  2016-04       Impact factor: 3.099

4.  Effectiveness of seasonal trivalent influenza vaccination against hospital-attended acute respiratory infections in pregnant women: A retrospective cohort study.

Authors:  Annette K Regan; Nicholas de Klerk; Hannah C Moore; Saad B Omer; Geoffrey Shellam; Paul V Effler
Journal:  Vaccine       Date:  2016-05-20       Impact factor: 3.641

5.  Population-Level Impact of Ontario's Infant Rotavirus Immunization Program: Evidence of Direct and Indirect Effects.

Authors:  Sarah E Wilson; Laura C Rosella; Jun Wang; Nicole Le Saux; Natasha S Crowcroft; Tara Harris; Shelly Bolotin; Shelley L Deeks
Journal:  PLoS One       Date:  2016-05-11       Impact factor: 3.240

6.  Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient.

Authors:  Aude G Chapuis; Sylvia M Lee; John A Thompson; Ilana M Roberts; Kim A Margolin; Shailender Bhatia; Heather L Sloan; Ivy Lai; Felecia Wagener; Kendall Shibuya; Jianhong Cao; Jedd D Wolchok; Philip D Greenberg; Cassian Yee
Journal:  J Exp Med       Date:  2016-05-30       Impact factor: 14.307
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.